- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | ANET |
|---|---|---|
| Founded | 1987 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 173.1B |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GILD | ANET |
|---|---|---|
| Price | $144.30 | $133.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 16 |
| Target Price | $146.50 | ★ $173.56 |
| AVG Volume (30 Days) | 4.9M | ★ 5.6M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 1684.21 | 23.32 |
| EPS | ★ 6.78 | 2.75 |
| Revenue | ★ $24,689,000,000.00 | $9,005,700,000.00 |
| Revenue This Year | $4.68 | $28.79 |
| Revenue Next Year | $6.10 | $21.10 |
| P/E Ratio | ★ $21.35 | $48.88 |
| Revenue Growth | 9.98 | ★ 28.60 |
| 52 Week Low | $95.30 | $59.43 |
| 52 Week High | $157.29 | $164.94 |
Technical Indicators
Market Signals| Indicator | GILD | ANET |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 48.11 |
| Support Level | $142.93 | $120.77 |
| Resistance Level | $149.38 | $140.39 |
| Average True Range (ATR) | 3.30 | 4.99 |
| MACD | -0.97 | 0.06 |
| Stochastic Oscillator | 20.04 | 55.62 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.